

## Clinical phenotype and outcomes of pneumococcal versus meningococcal purpura fulminans: a multicenter retrospective cohort study

Damien Contou, Nicolas de Prost, Laurent Argaud, Francois Barbier, Amélie Bazire, Gaetan Beduneau, Fréderic Bellec, Pascal Beuret, Pascal Blanc, Cedric Bruel, et al.

#### ▶ To cite this version:

Damien Contou, Nicolas de Prost, Laurent Argaud, Francois Barbier, Amélie Bazire, et al.. Clinical phenotype and outcomes of pneumococcal versus meningococcal purpura fulminans: a multicenter retrospective cohort study. Critical Care, 2021, 25 (1), pp.386. 10.1186/s13054-021-03812-1. hal-03426561v2

### HAL Id: hal-03426561 https://hal.science/hal-03426561v2

Submitted on 23 Nov 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

#### **RESEARCH LETTER**

**Open Access** 

# Clinical phenotype and outcomes of pneumococcal versus meningococcal purpura fulminans: a multicenter retrospective cohort study

Damien Contou<sup>1\*</sup> and Nicolas de Prost<sup>2</sup> on behalf of the HOPEFUL Study group

Keywords: Purpura fulminans, Neisseria meningitidis, Streptococcus pneumoniae, Septic shock, Meningitis

Purpura fulminans (PF) is a rare cause of septic shock characterized by the association of a sudden and extensive purpuric rash together with an acute circulatory failure [1] leading to high rates of intensive care unit (ICU) mortality [1, 2] and long-term sequelae [3]. Clinical presentation of patients with PF differs from that of patients with meningitis since PF patients are commonly admitted to the ICU for hemodynamic impairment exposing them to early death from refractory circulatory failure, as opposed to patients with meningitis who are usually admitted to the ICU for neurological impairment. Among adult patients, Neisseria meningitidis and Streptococcus pneumoniae are the most commonly involved microorganisms accounting for more than 80% of PF [1] and meningitis [4]. While clinical features and outcomes widely differ between adult patients with pneumococcal and meningococcal meningitis [4], it remains unclear whether pneumococcal (pPF) and meningococcal (mPF) PF exhibit different clinical phenotypes and outcomes, although pPF was previously shown to predominantly occur in asplenic patients [5] and carries a higher risk of limb amputation [1]. We therefore compared the clinical, biological presentations and outcome of adult patients with pPF and mPF.

\*Correspondence: damien.contou@ch-argenteuil.fr

We performed an ancillary analysis of a 17-year multicenter retrospective study conducted in 55 centers in France, which included all consecutive patients ( $\geq$  18 years) admitted to the ICU for an infectious PF (2000–2016) [1]. Patients with non-microbiologically documented PF or a bacterial documentation other than Neisseria meningitidis and Streptococcus pneumoniae were excluded.

During the study period, 195 patients with mPF and 67 with pPF were included. As compared to patients with mPF, those with pPF were older and had higher ICU severity scores. Chronic alcoholism and asplenia were more frequent in pPF, while the proportion of patients without previous comorbid conditions was lower. The time elapsed between disease onset and ICU admission was longer and purpura was less often noticed before ICU admission in pPF than in mPF. pPF patients also had lower platelet counts, higher serum urea and creatinine levels, and more frequent bacteremia. pPF patients needed more frequent invasive mechanical ventilation support, renal replacement therapy, plasma and platelets transfusions and had higher durations of invasive mechanical ventilation and vasopressor support. ICU mortality and rate of limb amputation were higher in patients with pPF (Table 1).

The Kaplan–Meier survival analysis did not show significant difference between pPF and mPF patients (p = 0.80 by the log-rank test, Fig. 1).



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/licenses/by/4.0/. The Creative Commons.org/licenses/by/4.0/. The Creative Commons.org/licenses/by/4.

<sup>&</sup>lt;sup>1</sup> Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prudhon, 95100 Argenteuil, France Full list of author information is available at the end of the article

Contou *et al. Critical Care* (2021) 25:386 Page 2 of 4

**Table 1** Comparison between meningococcal (n = 195) and pneumococcal (n = 67) purpura fulminans

	Meningococcal purpura fulminans $n = 195$	Pneumococcal purpura fulminans $n = 67$	<i>p</i> value
Patient's characteristics and ICU scores			
Male gender	97 (50)	37 (55)	0.527
Age, years	24 [19–45]	49 [38–60]	< 0.001
SAPS II	50 [35–66]	63 [58–72]	< 0.001
SOFA	11 [8–14]	14 [11–15]	< 0.001
Main comorbidities			
Chronic alcoholism	5 (2)	9 (13)	0.002
Diabetes mellitus	3 (2)	4 (6)	0.073
Asplenia or hyposplenia	3 (2)	34 (51)	< 0.001
Malignant hemopathy	1 (1)	2 (3)	0.162
Chronic respiratory disease	18 (23)	14 (28)	0.625
Immunocompromised status	5 (3)	4 (6)	0.241
No coexisting comorbid conditions	164 (84)	22 (33)	< 0.001
Clinical features upon ICU admission			
Days between disease onset and ICU admission, days	4 [4–5]	5 [4–6]	0.003
Headache	99 (51)	26 (39)	0.121
Myalgia	48 (25)	12 (18)	0.338
Digestive signs	124 (64)	41 (61)	0.839
Coma Glasgow score	15 [13–15]	15 [13–15]	0.751
Temperature, °C	38.5 [37–40]	38.5 [37–39]	0.802
Neck stiffness	52 (27)	6 (9)	0.004
Purpuric rash before ICU admission	168 (86)	38 (57)	< 0.001
β-Lactam antibiotic therapy before ICU admission	157 (81)	46 (69)	0.067
β-Lactam antibiotic therapy at ICU admission	195 (100)	67 (100)	_
Biological data upon ICU admission			
Leukocytes count, 10 <sup>3</sup> mm <sup>-3</sup>	10,700 [4000–20,800]	10,655 [2500–19,750]	0.717
Platelets count, 10 <sup>3</sup> mm <sup>-3</sup>	61,000 [28,500–100,000]	33,000 [19,000–49,500]	< 0.001
C-reactive protein, g/L	148 [90–247]	179 [141–289]	0.095
Procalcitonin, ng/mL	48 [14–100]	102 [55–164]	0.087
Troponin, mg/L	1 [0.10–12]	0.25 [0.13–11]	0.697
Creatine kinase, IU/L	300 [110–852]	812 [365–3460]	0.016
Serum urea, mmol/L	9 [7–11]	13 [11–15]	< 0.001
Serum creatinine, µmoL/L	190 [136–250]	240 [184–310]	< 0.001
Prothrombin time, %	33 [22–44]	29 [15–38]	0.227
Factor V, %	23 [10–49]	21 [9–29]	0.246
Arterial lactate, mmol/L	7.40 [5–11]	8 [6–11]	0.798
Fibrinogen, g/L	1.70 [0.6–3]	1.16 [0.5–2]	0.122
Microbiological data at ICU admission	1.7 0 [0.0 3]	1.10 [0.5 2]	0.122
Bacteremia Bacteremia	99 (51)	56 (84	< 0.001
Lumbar puncture performed	125 (64)	29 (43)	0.004
Positive cerebro-spinal fluid culture	72/125 (58)	11/29 (38)	0.080
Outcome in the ICU	72,123 (30)	11/25 (30)	0.000
Lowest LVEF, %	33 [20–45]	30 [25–50]	0.870
Inotropic agent	91 (64)	35 (61)	0.894
Platelets transfusion	57 (29)	46 (69)	< 0.001
Plasma transfusion	67 (34)	44 (66)	< 0.001
Steroids for septic shock or meningitis	116 (60)	45 (67)	0.333
Activated protein C	33 (17)	9 (13)	0.632
Invasive mechanical ventilation	152 (78)	65 (97)	0.032


Contou et al. Critical Care (2021) 25:386 Page 3 of 4

Table 1 (continued)

	Meningococcal purpura fulminans <i>n</i> = 195	Pneumococcal purpura fulminans $n = 67$	p value
Duration of tracheal intubation, days	4 [2–9]	10 [3–28]	< 0.001
Duration of vasopressors, days	3 [2–5]	5 [3–8]	< 0.001
Renal replacement therapy	69 (36)	45 (67)	< 0.001
Veno-arterial ECMO	7 (4)	6 (9)	0.104
Limb amputation	19 (10)	21 (31)	< 0.001
Limb amputation among ICU survivors	18/125 (14)	19/32 (59)	< 0.001
Death in ICU	70 (36)	35 (52)	0.027
Duration of ICU stay, days	5 [2–11]	14 [3–35]	< 0.001
Duration of hospital stay, days	12 [2–23]	23 [3–78]	0.003

Continuous variables are reported as median [Interquartile range] and compared between groups using the Student t-test. Categorical variables are reported as numbers (percentages) and compared using  $\chi^2$  test. A p value < 0.05 was considered significant

ICU intensive care unit; IMV Invasive Mechanical Ventilation, ECMO Extracorporeal membrane oxygenation, LVEF Left ventricular ejection fraction, SAPSII Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment



(blue curve) purpura fulminans

By multiple logistic regression adjusting on age, SOFA score, administration of β-lactam antibiotic therapy before ICU admission, platelet counts and arterial lactate levels, pPF was not associated with ICU mortality (adjusted Odds Ratio = 1.1595% CI 0.45-2.89, p = 0.77).

As already reported in adults patients with bacterial meningitis [4], this study confirms that significant differences exist between mPF and pPF, regarding both the clinical presentation at ICU admission and outcomes. Patients with pPF showed a different clinical phenotype, with less frequent purpura possibly leading to less frequent antibiotic treatment, more comorbidities with a more severe presentation at ICU admission, resulting in a higher rate of organ failures during ICU stay. Whether this more severe presentation should be ascribed to the level of virulence of the causative pathogen or to hostrelated characteristics is unsettled.

Our study has several limitations including its retrospective design and its long recruitment period with a high number of centers implying ICU procedures being

Contou et al. Critical Care (2021) 25:386 Page 4 of 4

inevitably heterogeneous. Nevertheless, the clinical presentation as well as the course in the ICU of patients with PF seem to differ according to the causative bacterium. This clinical observation should encourage researchers to better study the pathophysiology of pPF in order to develop targeted innovative therapies as being done for mPF [6].

#### **Abbreviations**

ICU: Intensive care unit; mPF: Meningococcal purpura fulminans; pPF: Pneumococcal purpura fulminans; SOFA: Sequential Organ Failure Assessment.

#### Acknowledgements

We thank the members of the HOPEFUL Study group (to be searchable through their individual PubMed records). Laurent Argaud (Lyon), François Barbier (Orléans), Amélie Bazire (Brest), Gaëtan Béduneau (Rouen), Frédéric Bellec (Montauban), Pascal Beuret (Roanne), Pascal Blanc (Pontoise), Cédric Bruel (Saint-Joseph), Christian Brun-Buisson (Mondor, AP-HP), Gwenhaël Colin (La Roche-sur-Yon), Delphine Colling (Roubaix), Alexandre Conia (Chartres), Rémi Coudroy (Poitiers), Martin Cour (Lyon), Damien Contou (Henri Mondor – AP-HP and Argenteuil), Fabrice Daviaud (Corbeil-Essonnes), Vincent Das (Montreuil), Jean Dellamonica (Nice), Nadège Demars (Antoine Beclère, AP-HP), Stephan Ehrmann (Tours), Arnaud Galbois (Quincy sous Sénart), Elodie Gelisse (Reims), Julien Grouille (Blois), Laurent Guérin (Ambroise Paré – AP-HP), Emmanuel Guérot (HEGP, AP-HP), Samir Jaber (Montpellier), Caroline Jannière (Créteil), Sébastien Jochmans (Melun), Mathieu Jozwiak (Kremlin Bicêtre, AP-HP), Pierre Kalfon (Chartres), Antoine Kimmoun (Nancy), Alexandre Lautrette (Clermont Ferrand), Jérémie Lemarié (Nancy), Charlène Le Moal (Le Mans), Christophe Lenclud (Mantes La Jolie), Nicolas Lerolle (Angers), Olivier Leroy (Tourcoing), Antoine Marchalot (Dieppe), Bruno Mégarbane (Lariboisière, AP-HP), Armand Mekontso Dessap (Mondor, AP-HP), Etienne de Montmollin (Saint-Denis), Frédéric Pène (Cochin, AP-HP), Claire Pichereau (Poissy), Gaëtan Plantefève (Argenteuil), Sébastien Préau (Lille), Gabriel Preda (Saint-Antoine, AP-HP), Nicolas de Prost (Henri Mondor, AP-HP), Jean-Pierre Quenot (Dijon), Sylvie Ricome (Aulnay-sous-Bois), Damien Roux (Louis Mourier, AP-HP), Bertrand Sauneuf (Cherbourg), Matthieu Schmidt (Pitié Salpétrière, AP-HP), Guillaume Schnell (Le Havre), Romain Sonneville (Bichat, AP-HP), Jean-Marc Tadié (Rennes), Yacine Tandjaoui (Avicenne, AP-HP), Martial Tchir (Villeneuve Saint Georges), Nicolas Terzi (Grenoble), Xavier Valette (Caen), Lara Zafrani (Saint-Louis, AP-HP), Benjamin Zuber (Versailles).

#### Authors' contributions

DC and NDP are responsible for the conception and design. All the authors were responsible for analysis and interpretation of data. All authors read, critically reviewed and approved the final manuscript. DC takes responsibility for the paper as a whole. All authors read and approved the final manuscript.

#### Funding

No funding.

#### Availability of data and materials

The dataset used and analyzed for the current study is available from the corresponding author on reasonable request.

#### **Declarations**

#### Ethics approval and consent to participate

This study was conducted in accordance with the amended Declaration of Helsinki and was approved by the Institutional Review Board (CE 2016–01) of the French Intensive Care Society in March, 2016.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that they have no competing interests.

#### **Author details**

<sup>1</sup> Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prudhon, 95100 Argenteuil, France. <sup>2</sup> Service de Médecine Intensive Réanimation, Groupe de Recherche CARMAS, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, 51, avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.

Received: 28 October 2021 Accepted: 4 November 2021 Published online: 11 November 2021

#### References

- Contou D, Sonneville R, Canoui-Poitrine F, Colin G, Coudroy R, Pène F, et al. Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study. Intensive Care Med. 2018:44:1502–11.
- Contou D, Mekontso Dessap A, de Prost N. Extracorporeal membrane oxygenation in adult patients with purpura fulminans. Crit Care Med. 2019;47:e1039–40.
- Contou D, Canoui-Poitrine F, Coudroy R, Préau S, Cour M, Barbier F, et al. Long-term quality of life in adult patients surviving purpura fulminans: an exposed-unexposed multicenter cohort study. Clin Infect Dis. 2018;6:66.
- van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351:1849–59.
- Contou D, Coudroy R, Colin G, Tadié J-M, Cour M, Sonneville R, et al. Pneumococcal purpura fulminans in asplenic or hyposplenic patients: a French multicenter exposed-unexposed retrospective cohort study. Crit Care. 2020;24:68.
- Denis K, Le Bris M, Le Guennec L, Barnier J-P, Faure C, Gouge A, et al. Targeting Type IV pili as an antivirulence strategy against invasive meningococcal disease. Nat Microbiol. 2019;4:972–84.

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$  thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

**Learn more** biomedcentral.com/submissions

